Vertex Pharmaceuticals Inc / Ma (VRTX)

Historical Portfolio Holders from 2014 to 2024

All holders as of
Q1 2024
Type / Class
Equity / COM
Shares, Excl. Options Q1 2024
$225M
Holdings value Q1 2024
$94.1B
Value change Q1 2024
-$1.68B
Grand Portfolio weight change Q1 2024
-0.004%
Number of holders
1481
Number of Buys Q1 2024
718
Number of Sells Q1 2024
-572
Average Buys Q1 2024 %
+0.014%
Average Sells Q1 2024 %
-0.009%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Filings
Period Shares, Excl. Options Value, Excl. Options Change Price Filings
2024 Q1 225M $94B -$1.7B $418.01 1,443
2023 Q4 229M $93.1B +$943M $406.89 1,459
2023 Q3 231M $80.4B -$572M $347.74 1,303
2023 Q2 234M $82B -$504M $351.91 1,300
2023 Q1 236M $73.7B +$1.22B $315.07 1,219
2022 Q4 236M $68B +$103M $288.78 1,249
2022 Q3 236M $68.2B +$774M $289.54 1,158
2022 Q2 234M $65.7B +$843M $281.79 1,129
2022 Q1 234M $60.7B +$1.52B $260.97 1,097
2021 Q4 229M $50.2B +$213M $219.60 1,067
2021 Q3 231M $41.7B +$181M $181.39 966
2021 Q2 232M $46.6B -$77.2M $201.63 1,013
2021 Q1 235M $50.4B -$314M $214.89 1,029
2020 Q4 239M $56.3B +$122M $236.34 996
2020 Q3 242M $65.8B +$80.1M $272.12 978
2020 Q2 242M $70.3B -$159M $290.31 988
2020 Q1 244M $58B +$555M $237.95 892
2019 Q4 243M $53.3B -$485M $218.95 853
2019 Q3 246M $41.6B +$144M $169.42 747
2019 Q2 246M $45B +$1.36B $183.38 755
2019 Q1 245M $45.1B +$491M $183.95 777
2018 Q4 243M $40.3B +$454M $165.71 742
2018 Q3 241M $46.5B +$429M $192.74 736
2018 Q2 241M $41B +$644M $169.96 727
2018 Q1 241M $39.2B +$419M $162.98 718
2017 Q4 240M $35.9B +$453M $149.86 679
2017 Q3 238M $36.1B +$466M $152.04 652
2017 Q2 236M $30.4B +$235M $128.87 607
2017 Q1 236M $25.8B +$2.29B $109.35 558
2016 Q4 236M $17.4B -$239M $73.67 516
2016 Q3 241M $21B +$288M $87.21 513
2016 Q2 240M $20.6B +$109M $86.02 503
2016 Q1 242M $18.8B +$800M $79.49 516
2015 Q4 235M $29.5B +$301M $125.83 545
2015 Q3 235M $24.5B +$825M $104.14 522
2015 Q2 230M $28.1B -$244M $123.48 524
2015 Q1 233M $27.5B +$590M $117.97 497
2014 Q4 230M $27.3B -$396M $118.80 508
2014 Q3 233M $26.2B +$1.15B $112.31 467
2014 Q2 227M $21.5B +$372M $94.68 454
2014 Q1 223M $15.8B +$175M $70.72 426